You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥首張XPO1抑制劑處方落地海南先行區 塞利尼索成為特批帶離藥物
格隆匯 04-29 07:32

近日,全球首創選擇性核輸出抑制劑塞利尼索(selinexor, XPOVIO)在海南博鰲樂城先行區博鰲超級醫院開出中國大陸首張處方,並獲准帶離使用。據悉,塞利尼索是全球首款選擇性核輸出XPO1抑制劑,獲美國食品藥品監督管理局(FDA)批准用於多發性骨髓瘤和瀰漫性大B細胞淋巴瘤,目前共有5種治療血液瘤的方案被納入美國國家綜合癌症網絡指南。德琪醫藥(6996.HK)是項目引進的牽頭單位。塞利尼索在中國大陸的處方落地,使國內患者能與全球同步分享這一全新機制的抗腫瘤藥物,對提高國內血液腫瘤治療現狀具有里程碑意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account